BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ... [Yahoo! Finance]
BioCryst Pharmaceuticals, Inc. (BCRX)
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
biocryst.gcs-web.com/investor-relations
Company Research
Source: Yahoo! Finance
Ex-US ORLADEYO Sales: $13.2 million (11.3% of total ORLADEYO revenue). Operating Expenses (excluding non-cash stock compensation): $92.2 million. Stock Compensation: $17.2 million. GAAP Operating Expenses: $109.4 million. Operating Profit (excluding non-cash stock compensation): $24.9 million. Operating Profit (including non-cash stock compensation): $7.7 million. Cash Position: $351.7 million at the end of the quarter. Net Cash Flow: Positive over $13 million for the quarter. 2024 Revenue Guidance for ORLADEYO: $430 million to $435 million. Total Company Revenue Guidance: $443 million to $448 million. Operating Expenses Guidance: $380 million to $390 million. Warning! GuruFocus has detected 6 Warning Signs with BCRX. Release Date: November 04, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript BioCryst Pharmaceuticals Inc ( NASDAQ:BCRX ) reported a nearly 36% year-over-year growth in ORLADEYO revenue,
Show less
Read more
Impact Snapshot
Event Time:
BCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCRX alerts
High impacting BioCryst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
BCRX
News
- BioCryst Launches ORLADEYO® (berotralstat) in PortugalGlobeNewswire
- BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress [Yahoo! Finance]Yahoo! Finance
- BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint CongressGlobeNewswire
- BioCryst to Report Fourth Quarter 2024 Financial Results on February 24GlobeNewswire
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
BCRX
Earnings
- 11/4/24 - In-Line
BCRX
Sec Filings
- 1/13/25 - Form 8-K
- 1/10/25 - Form 8-K
- 1/8/25 - Form 8-K
- BCRX's page on the SEC website